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ABSTRACT: The insulin from the Atlantic hagfish (Myxine glutinosa) has been one of the most studied insulins
from both a structural and a biological viewpoint; however, some aspects of its biology remain controversial,
and there has been no satisfying structural explanation for its low biological potency. We have re-examined
the receptor binding kinetics, as well as the metabolic and mitogenic properties, of this phylogenetically
ancient insulin, as well as that from another extant representative of the ancient chordates, the river lamprey
(Lampetra fluviatilis). Both insulins share unusual binding kinetics and biological properties with insulin
analogues that have single mutations at residues that contribute to the hexamerization surface. We propose
and demonstrate by reciprocal amino acid substitutions between hagfish and humaninsulins that the reduced
biological activity of hagfish insulin results from unfavorable substitutions, namely, A10 (Ile to Arg), B4 (Glu
to Gly), B13 (Glu to Asn), and B21 (Glu to Val). We likewise suggest that the altered biological activity of
lamprey insulin may reflect substitutions at A10 (Ile to Lys), B4 (Glu to Thr), and B17 (Leu to Val). The
substitution of Asp at residue B10 in hagfish insulin and of His at residue A8 in both hagfish and lamprey
insulinsmayhelpcompensateforunfavorablechangesinotherregionsofthemolecules. Thedatasupportthe
concept that the set of unusual properties of insulins bearing certain mutations in the hexamerization surface
may reflect those of the insulins evolutionarily closer to the ancestral insulin gene product.
Insulin belongs toa superfamilyof structurally related peptide
hormonesessentialforgrowth,development,reproduction,long-
evity, and metabolism (reviewed in refs 1 and 2). In humans,
members of this family include insulin, the insulin-like growth
factors (IGF-I and IGF-II), relaxins (H1, H2, and H3), INSL3,
INSL4, INSL5, and INSL6 (reviewed in ref 3).
Insulin, IGF-I, and IGF-II bind to receptors that share
sequence and structural features. They belong to a superfamily
of receptor tyrosine kinases, which in vertebrates includes the
insulin receptor,the type I IGF
1 receptor,andthe orphaninsulin
receptor-related receptor (reviewed in ref 4). In contrast, the
relaxin-like members bind to G protein-coupled receptors with
seven transmembrane domains (reviewed in ref 5).
Distinct insulin and IGF-I-like molecules have been cloned in
vertebrate species, including extant representatives of ancient
chordates, such as the Atlantic hagfish (Myxine glutinosa)( 6-8)
andlamprey(LampetrafluviatilisandPetromyzonmarinus)( 9,10).
Likewise, separate insulin and IGF-I receptors have been cloned
in these animals (11).
The study of insulins from various species has shed light not
onlyonthe evolution ofthe molecule butalsoon the relationship
between insulin structureand activity. The finding that a number
of amino acids were highly conserved during evolution led to the
suggestionthatadozenoftheseresidueslocatedonthesurfaceof
the molecule were involved in receptor binding and biological
activity. This cluster of residues is now termed the “classical
binding surface” or “site 1” (12-15) (see Table 1). Some of the
same residues are involved in the dimerization of the insulin
molecule (14).
Early studies of the biological properties of hagfish insulin
generated somewhat conflicting results. The affinity of hagfish
insulin for isolated rat adipocytes was determined to be 23% of
that of porcine insulin, while its biological potency in stimulating
lipogenesis in the same cells was only 3-5% (16-18). Others,
however, found an affinity for isolated rat hepatocytes or human
IM-9 receptors more consistent with the biological potency
(19, 20). Indeed, studies of the receptor binding kinetics of
125I-labeled hagfish insulin demonstrated that this insulin had
anunusually slowassociation rate (21).Consequently, the earlier
studies comparing affinity and biological activity were not
performed under equilibrium conditions, and affinity was there-
fore underestimated. Another anomalous behavior seen with
hagfish insulin was a dose-response curve for accelerating the
dissociation of
125I-labeled porcine insulin from IM-9 cell recep-
tors [measuring the so-called negative cooperativity (see ref 22)]
that was not bell-shaped (19).
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These data together with the fact that Ala substitutions in
human insulin at A13 and B17 showed the same binding proper-
ties as hagfish insulin were used to propose a novel binding
surface (“site 2”, which coincides more or less with insulin’s
hexamerizationsurface) (22-24).Thissurfacewasmapped more
recently by alanine mutagenesis of insulin using high-affinity
binding to IM9 cells (see Table 1) (1, 15, 25, 26), supporting the
cross-linking binding model proposed by De Meyts (22)a n d
Sch€ affer (24) in 1994. The model proposed by De Meyts (22)i n
which site 1 and site 2 on the insulin molecule alternatively cross-
link two receptor R-subunit binding surfaces (site 1 and site 2)
with an antiparallel disposition has been supported by the recent
crystalstructureoftheinsulinreceptorectodomain(27)aswe llas
by alanine scanning mutagenesis of the insulin receptor (28, 29)
and mathematical modeling (30).
However, to date no rational explanation for the aberrant
binding behavior of hagfish insulin has been provided.
In this work, we have re-examined the binding behavior and
biological properties of hagfish insulin as well as that of insulin
fromtheriverlamprey(L.fluviatilis).Structurally,hagfishinsulin
is 65% identical to human insulin, bearing 19 amino acid
substitutions. In comparison, the sequence similarity of lamprey
insulin with human insulin is 72%, with 14 amino acid substitu-
tionsaswellasapentapeptideextensionattheN-terminus(Table
1 of the Supporting Information). Both insulins have a single-
residue extension at the C-terminus of the B chain. By analyzing
singlysubstituted human andhagfish insulin analogues,weshow
that a small number of residues explain the aberrant behavior of
hagfish and lamprey insulins.
EXPERIMENTAL PROCEDURES
Materials. Molecular biology procedures, including agarose
gel electrophoresis,restriction enzyme digestion, ligation, bacter-
ial transformation, and DNA sequencing, were performed by
standard methods. Oligonucleotides were purchased from DNA
Technology (Aarhus, Denmark). Restriction enzymes and ligase
were from New England BioLabs (Hitchin, U.K.). Recombinant
human insulin,
125I-Tyr
A14 insulin, and Achromobacter lyticus
protease were from Novo Nordisk A/S (Bagsværd, Denmark).
IM9 cells were purchased from ATCC (Middlesex, U.K.).
Hagfish insulin was a gift from S. Falkmer (University of Umea,
Umea, Sweden). Lamprey insulin was purified to near homo-
geneity (>98% pure) from the islet organ of the river lamprey
L. fluviatilis as previously described (9). Both hagfish and
lamprey insulins were labeled at Tyr
A14 at Novo Nordisk’s
Chemistry and Isotope laboratory using the lactoperoxidase
method and high-performance liquid chromatography (HPLC)
purification (31). Hagfish cDNA production was described
previously (32).
Vector Construction and Yeast Expression of Insulin
Analogues. Substitutions were introduced into the sequence
encoding the insulin precursor by QuikChange site-directed
mutagenesis (Stratagene). Resultant constructs were subcloned
into yeast expression vector pIM45 (kind gift from J. Brandt,
Novo Nordisk A/S). The yeast expression procedure has been
described previously (33). Briefly, an insulin precursor was
coupled to a synthetic prepropeptide sequence consisting of a
prepropeptide, a KR Kex2 cleavage site, a removable spacer
peptide E(EA)3EPK, and insulin precursor (B1-B29/B30)-
AAK-(A1-A21). The hagfish insulin cDNA was inserted into
pIM45 using standard PCR and restriction enzyme digestion/
ligation. To express the hagfish insulin in the system, we
substituted Lys at positions A9 and B9 with Ser (like in human
insulin) to prevent cleavage at these positions during processing,
and we removed residue Met-B31, leading to the sequence
Glu-(Glu-Ala)3-Glu-Pro-Lys-(B1-B30)-(A1-A21). The single-
chain insulin precursor was expressed in Saccharomyces cerevi-
siae strain MT663. Yeast cells were transformed and selected on
yeastnitrogenbase/2%glucoseplates.Yeastculturesweregrown
in yeast/peptone medium with 2% glucose and 50 mM CaCl2 for
72 h at 30  C( 33, 34).
Maturation and Purification of the Insulin Precursor.
The single-chain insulin precursors were converted to des-B30-
insulin using a lysine specific endoprotease (A. lyticus)t h a t
removes the spacer peptide (34). The pH of the cell-free yeast
culture medium with the insulin precursor was adjusted to >8.5
Table 1: Sequence Alignment and Comparison of Residues of Human, Hagfish, and Lamprey Insulin in Classical and Novel Binding Surfaces
a
Classical Binding Surface (Site 1)
Al A2 A3 A5 A8 A19 A21 B12 B16 B23 B24 B25 B26
human Gly Ile Val Gln Thr Tyr Asn Val Tyr Gly Phe Phe Tyr
hagfish -- --His --------
lamprey -- --His --------
Novel Binding Surface (Site 2)
A12 A13 A17 B10 B13 B17
human Ser Leu Glu His Glu Leu
hagfish - Ile - Asp Asn Ile
lamprey - Ile ---Val
Other Sites
A9 A10 A15 A16 Bl B2 B3 B4 B21 B29 B30 B31
human Ser Ile Gln Leu Phe Val Asn Gln Glu Lys Thr -
hagfish Lys Arg Asp - Arg Thr Thr Gly Val Thr Lys Met
lamprey Arg Lys Asp Met Ala Gly Gly Thr Asp Ser Lys Thr
aDashes represent identical residues compared to that of human insulin. The sequences are shown with the three-letter code for the amino acids.Article Biochemistry, Vol. 48, No. 47, 2009 11285
with 1 M Tris-HCl (pH 9), and the mixture was applied to a
column with A. lyticus immobilized on Sepharose. The column
was incubated for 30-60 min at room temperature before the
cleaved precursor was eluted from the column with 50 mM Tris-
HCl. The insulin analogues were analyzed by mass spectroscopy
and were shown to have correct masses. Quantitation was
performed by liquid chromatography and mass spectroscopy
(LC-MS) using human insulin as a standard.
Binding Assays. Whole cell receptor binding assays were
performedaspreviouslydescribed(35,36)usingIM9cells,which
strongly express the IR-A isoform (ca. 20000 binding sites/cell).
All experiments were repeated three times in duplicate unless
otherwise stated.
For association assays, 1   10
7 cells/mL were incubated with
150000 cpm/mL
125I-labeled human, hagfish, or lamprey insulin
at 15  C. At specified time points, duplicate 200 μLa l i q u o t sw e r e
centrifuged through 200 μL of ice-cold HBB [100 mM Hepes,
100 mM NaCl, 5 mM KCl, 1.3 mM MgSO4, 1 mM EDTA,
10 mM glucose, 15 mM sodium acetate, and 1% BSA (w/v)
(pH 7.6)]. The bound
125I-labeled ligandwas counted ina Wallac
WIZARD γ counter (Perkin-Elmer). Two additional aliquots
were not centrifuged but counted as the total.
Dissociation kinetics were determined as previously de-
scribed (36). Cells were incubated with
125I-labeled lamprey or
human insulin for 6 h at 15  C. The cells were centrifuged, the
supernatants aspirated, and the cell pellets resuspended in an
equivalent volume of fresh HBB. The samples were then diluted
40-fold in the absence or presence of 170 nM human insulin.
Duplicate tubes were centrifuged at the specified times to
determine the cell-bound counts per minute.
For dose-response curves for negative cooperativity (acce-
lerated dissociation) (36), 5   10
7 cells/mL were incubated with
125I-labeled hagfish, lamprey, or human insulin (150000 cpm/mL
ofcells)for2or4hat15 C.Afterward,thecellswerecentrifuged
and the supernatant (unbound ligand) was removed. The cell
pellet was resuspended to the same concentration in HBB, and
25 μL aliquots of cells were transferred to tubes containing
increasing concentrations of cold analogue in 1 mL of HBB at
15  C. The dissociation of prebound ligand was stopped after
30 min by centrifugation at 4000 rpm for 5 min. The pellet was
counted in the γ counter.
For competition assays, 2.5   10
6 or 1   10
7 cells/mL were
incubated with
125I-labeled ligand (20000 cpm) in the presence of
increasing concentrations of the analogue in a final volume of
500 μLf o r2 . 5o r6ha t1 5 C in HBB. Afterward, duplicate
200 μL aliquots were transferred to centrifuge tubes and cen-
trifuged at 14000 rpm for 5 min. The bound
125I-labeled ligand
wascounted.Bindingdatawerecorrectedfornonspecificbinding
and analyzed by computer fitting to a one-site model using an
Excel program developed from the model of Wang (37)i no u r
laboratory by A. V. Groth and R. M. Shymko, yielding the
dissociation constant (Kd).
Metabolic Potency. Insulin-stimulated lipogenesis in freshly
isolated rat adipocytes was used to evaluate metabolic potency.
Isolated rat adipocytes were prepared by a modification of the
method of Gliemann (38) from the epididymal fat pads of male
Sprague-Dawley rats. Adipose tissue was digested with 1 mg/mL
collagenase (Sigma catalog no. C6885) in Krebs Ringers Hepes
buffer (KRH) containing 3.5% (w/v) BSA (Sigma catalog no.
A4503), 0.2 μM adenosine, and 2 mM glucose for 45 min at
37  C. The adipocytes were washed three times in washing buffer
[KRH containing 1% (w/v) BSA, 0.2 μM adenosine, and 2 mM
glucose] and resuspended in incubation buffer (KRH containing
3.5% BSA, 0.56 mM glucose, and 0.2 μM adenosine). Lipocrit
was used as a measure of cell number. Hormone-stimulated
conversion of glucose into lipids was measured by the method of
Moody et al. (39) using triplicate determinations for each point.
Briefly, 0.5% (v/v) adipocytes were incubated for 2 h at 37  C
in 0.5 mL of incubation buffer containing 0.05 mCi of [3-
3H]-
D-glucose (TRK239, Amersham) and various concentrations of
hagfish, lamprey, or human insulin. Incubation was terminated
by the addition of 3 mL of BetaMax scintillator (ICN, Costa
Mesa, CA), and total lipids were extracted by allowing the
samples to stand for 24 h at 4  C. Under these conditions,
unmetabolized labeled glucose is not extracted into the organic
phase and is not counted. We measured the background by
preparing samples with a tracer but without hormone and
FIGURE 1: Associationanddissociationassay.(AandB)Association
of
125I-labeled lamprey and hagfish insulin with IM9 cells. The
fraction of tracer bound over total is expressed as a function of
incubation time. Panel A depicts data from a representative experi-
ment comparing
125I-labeled human insulin (b)a n d
125I-labeled
lamprey insulin (2), while panel B depicts datafroma representative
experiment comparing
125I-labeled human insulin (b)a n d
125I-labe-
led hagfish insulin (9). (C) Representative curves of dissociation of
125I-labeled human (b)a n d
125I-labeled lamprey (2)i n s u l i ni n
dilution alone (filled symbols) or in the presence of 1 μg/mL human
insulin (empty symbols). Bound tracer at time t as a fraction (%) of
bound tracer at time zero was plotted as a function of time.11286 Biochemistry, Vol. 48, No. 47, 2009 Sajid et al.
immediately adding scintillant. Samples were counted in a β
counter (Tricarb 460 C Liquid Scintillation System) for 10 min
and the counts corrected for background. Data were fitted to a
four-parameter logistics model (40, 41) in Microsoft Excel to
determine the concentration that produces 50% of the maximal
stimulation (ED50).
Mitogenic potency was measured by thymidine incorpora-
tion. NIH 3T3 fibroblasts stably transfected with wild-type
human insulin receptor [clone HIR 3.5 (42)] were obtained
from K. Siddle (Cambridge, U.K.). The cells were cultured
with Dulbecco’s Minimal Essential Medium (DMEM) supple-
mented with 10% FBS, penicillin, streptomycin, sodium pyru-
vate, and 2 mM glutamine in a humidified atmosphere. HIR
3.5 cells were plated at a density of 10000 cells/well in 96-well
microtiter plates and allowed to attach overnight in DMEM
containing 10% FBS. Quiescence was achieved after starva-
tion for 2 days in DMEM with 2% FBS at which time hagfish,
lamprey, or human insulin was added at increasing concentra-
tions with vehicle alone as a negative control and 10% FBS as
a positive control. After incubation for 17 h at 37  C, the cells
were pulse-labeled with 1 μCi of [
3H]thymidine (TRK565,
Amersham) per well for 3 h. Unincorporated label was removed
by washing twice with PBS, and the cells were then solubilized
with0.2MNaOH. A200 μLvolumeof SuperMixScintillation
f l u i d( W a l l a c )w a sa d d e da n da l l o w e dt om i xf o r1ho nap l a t e
shaker. Incorporation of [
3H]thymidine was determined by
β radiationcounting(MicroBeta,Wallac).Datawereanalyzed
using a four-parameter logistics model as described for lipo-
genesis (see above).
RESULTS
Association Kinetics of Hagfish and Lamprey Insulin for
the Membrane-Bound Human Insulin Receptor. The kine-
tics of association of hagfish and lamprey insulin with the
human insulin receptor on IM9 cells were determined at 15  C
using
125I-labeledhagfish,lamprey,andhumaninsulin(Figure
1A,B). The association rates for both hagfish and lamprey
insulins were much slower than that of human insulin. Via
comparison of the initial slopes of the association curves,
the initial rate for the lamprey insulin appeared to be
9.4-fold slower than that of human insulin while that of the
hagfish insulin appeared to be ∼21-fold slower than that of
human insulin. An apparent steady state of binding was
reached after 6 h at 15  C with lamprey insulin; 4 h was
required for hagfish insulin, while human insulin required
incubation for 2.5 h.
KineticsofDissociationof
125I-LabeledLampreyInsulin
from the Human Insulin Receptor. Dissociation of
125I-
labeled human insulin by dilutionalone showed anon-first-order
biphasic pattern and was markedly accelerated in the presence of
170 nM unlabeled human insulin as previously described (12, 22,
36) (Figure 1C). The dissociation of
125I-labeled lamprey insulin
by dilution alone was much slower than that of
125I-labeled
human insulin, andinthe presence of170 nM human insulin,the
dissociationoflampreyinsulinwasonlyminimallyaccelerated to
a rate similar to the rate of dissociation of human insulin by
dilution alone(Figure1C). Similarresultswereshownpreviously
for hagfish insulin (43).
FIGURE 2: Dose-responsecurvesforligand-inducedaccelerationofdissociation.PanelAillustratesdose-responsecurvesforthehumaninsulin
tracerinthepresenceofunlabeledinsulin(b),thehumaninsulintracerinthepresenceofunlabeledlampreyinsulin(O),thelampreytracerinthe
presence of unlabeled human insulin (4), and the lamprey tracer in the presence of unlabeled lamprey insulin (2). Panel B illustrates
dose-response curves for the human insulin tracer in the presence of unlabeled insulin (b), the hagfish tracer in the presence of unlabeled
human insulin (0), and the hagfish tracer in the presence of unlabeled hagfish insulin (9). Panel C is an expansion of the plot of panel A, while
panel D is an expansion of the plot of panel B. These expanded scales more clearly demonstrate the presence of reduced negative cooperativity.Article Biochemistry, Vol. 48, No. 47, 2009 11287
Dose-Response Curves for Accelerated Ligand Disso-
ciation (negative cooperativity). The amount of tracer bound
after dissociation for 30 min was measured as a function of the
concentration of unlabeled ligand to determine the dose-
response curve for negative cooperativity (Figure 2) (22, 36).
Dissociation of
125I-labeled human insulin from the human
insulin receptor by human insulin produced a bell-shaped curve
as previously reported and shown in Figure 2A,B (22, 36).
Unlabeled lamprey insulin induced the same maximal accelera-
tion of dissociation of
125I-labeled human insulin as unlabeled
human insulin, with a rightward shift in the curve reflecting the
reduced affinity of this insulin for the human insulin receptor
(Figure 2A). Similar results have previously been shown with
hagfishinsulin(19).Bothlampreyandhagfishinsulindisplayeda
decrease in the maximal rate of acceleration of dissociation
obtained with cold ligand when these insulins were used as the
tracer as seen in Figure 2A,B and on an expanded scale in panels
C and D of Figure 2(20 and 56%, respectively, of the insulin
tracer). In contrast to unlabeled human insulin, there was no
reversal of cooperativity at high concentrations with either
lamprey or hagfish insulin when the homologous tracer was
used. This was also reported previously with unlabeled hagfish
insulin and a porcine tracer (19).
AffinitiesofLampreyandHagfishInsulinfortheHuman
Insulin Receptor. The affinities of hagfish and lamprey insulin
for the human insulin receptor on IM-9 cells were determined in
competition studies using constant tracer concentrations of
125I-
labeled human, hagfish, and lamprey insulin and increasing
concentrations of the homologous unlabeled ligands. Competi-
tion studies were also performed using
125I-labeled human and
lamprey insulin with the heterologous insulin as the competitor
(data not shown). To allow for the system to reach steady state
for the slower associating insulins, the assay was performed at
15 Cfor6h.Asdepictedinthecompetitioncurves(Figure3A,B),
both hagfish and lamprey insulin have a reduced affinity relative
to that of human insulin on the membrane-bound receptor.
Lamprey insulin had a relative affinity of 8% relative to that of
human insulin, while the relative affinity of hagfish insulin was
4.5%.
Lipogenesis in Primary Rat Adipocytes. Conversion of
[
3H]glucose into lipids in isolated primary rat adipocytes was
usedtomeasurethemetabolicpotencyofthetwoancientinsulins
(Figure4A).Datafromthree experimentsperformed intriplicate
wereaveragedandfittedtoafour-parameterlogisticsmodel,and
FIGURE 3: Homologous competition for the holo insulin receptor.
All curves are plotted as bound:total tracer as a function of the
logarithm of the concentration of unlabeled ligand. Competition of
125I-labeled human insulin with increasing concentrations of human
insulin(b)isillustratedinthetwopanels.Competitionof
125I-labeled
lamprey insulin (2) is shown in panel A and
125I-labeled hagfish
insulin (9) in Panel B. Data points are averages of duplicate values
from a representative experiment.
FIGURE 4: Functional studies. (A) Dose-response curves for stimu-
lation of lipogenesis in primary rat adipocytes. Lamprey (2)a n d
hagfish (9) insulins were compared to human insulin (b) for their
ability to stimulate lipogenesis in primary rat adipocytes. Data are
averages( the standarddeviation ofthreeexperimentsperformedin
triplicateandhavebeenfittedusingafour-parameterlogisticsmodel.
It is plotted as a percentage of the maximum obtained with human
insulin as a function of ligand concentration. Panel B illustrates the
mitogenic potency by [
3H]thymdine incorporation of NIH 3T3 cells
overexpressing the insulin receptor. Lamprey (2) and hagfish (9)
insulins were compared to human insulin (b) in their ability to
promote DNA synthesis. Data presented are averages of at least
three experiments (performed in triplicate) ( the standard deviation
and have been fitted to a four-parameter logistics model. Data are
plottedasthepercentageofthemaximumobtainedwith10%FBSas
a function of ligand concentration.11288 Biochemistry, Vol. 48, No. 47, 2009 Sajid et al.
ED50 was calculated. In response to insulin, isolated rat adipo-
cytes incorporate labeled glucose into lipids in a dose-dependent
mannerwithanED50of33pM.Bothhagfishandlampreyinsulin
produced the same maximal lipogenesis as human insulin, indi-
cating they are fullagonists. However, thepotencies were 9.4and
8.4% of that of human insulin for lamprey (ED50 =3 5 8p M )a n d
hagfish insulin (ED50 = 400 pM), respectively.
Thymidine Incorporation. Incorporation of [
3H]thymidine
intoDNAbyhagfish,lamprey,andhumaninsulinwasmeasured
in NIH 3T3 fibroblasts overexpressing the wild-type human
insulin receptor to determine the mitogenic potency of hagfish
and lamprey insulin (Figure 4B). The response to 10% FBS was
used as an indicator of the maximal response, and data are
expressed as the percent of the maximal signal obtained with
serum. Potency was calculated by fitting the data from three
experiments performed in triplicate to a four-parameter logistics
model. Human insulin stimulated DNA synthesis with an ED50
of 1.92 nM, while the ED50 was 3.55 nM for lamprey insulin and
5.95 nM for hagfish insulin, demonstrating potencies of 54 and
32%, respectively. Lamprey insulin produced the same maximal
response as serum or human insulin, while the maximal stimula-
tionbyhagfishinsulinreachedonly75%ofthatofhumaninsulin
(the difference was not statistically significant).
Thus, it appears that hagfish insulin has a relative mitogenic
potency that is 3.8 times greater than its relative metabolic
potency, and for lamprey insulin, the relative potency is 5.8-fold
greater than its relative metabolic potency.
Production, Quantitation, and Binding of the Human
Insulin Analogues. Eight human insulin analogues were pro-
duced, each containing a single substitution (and one with a
double substitution) found in hagfish insulin. The substitutions
were selected on the basis of structure-activity relationship
considerations of hagfish insulin (see the details in Discussion).
All the analogues were expressed successfully in S. cerevisiae and
had the correct molecular weights as determined by mass
spectrometry (data not shown).
Heterologous competition assays were performed using
125I-
labeled human insulin to measure changes in the affinity of the
analogues compared to human insulin. The average Kd value for
each analogue ( the standard deviation (SD) is given in Table 2.
Not surprisingly, the two analogues having the conserved Leu to
Ile substitution show affinity similar to that of human insulin.
Five of the single analogues, IleA10Arg, HisB10Asp, Glu-
B13Asn, GluB21Val, and the double substitution (GlnB4Gly
andGluB13Asn), showed a >2-fold change in affinity (Table 2).
The 2-fold changes were used as a cutoff on the basis of alanine
scanningmutagenesis studies,which have demonstrated that any
meaningful change in affinity produced by a single substitution
ranges from 2- to 100-fold (44, 45).
Thesinglysubstitutedanaloguethatshowedthelowestaffinity
was IleA10Arg. Replacing Ile with Arg had a large impact on
receptor binding, leading to an almost 16-fold decrease in
affinity. The GluB13Asn analogue exhibited the second largest
decrease in affinity, 8-fold. Introducing Val instead of Glu at
position B21 resulted in a 4-fold decrease in affinity. The
GlnB4Gly analogue exhibited a borderline 1.9-fold decrease in
affinity but when combined with the B13 substitution showed a
13-fold decrease, close to an additive effect. The HisB10Asp
substitution showed a 5-fold increase in affinity as reported
previously (31, 46).
Production, Quantitation, and Binding of the Hagfish
Insulin Analogues. Having established that these candidate
residues may explain the low affinity of hagfish insulin, we
decided to express hagfish insulin with reciprocal substitutions.
Heterologous competition assays were again performed on the
cell-bound receptors to determine any changes in the affinity of
the hagfish analogues with human substitutions compared to
humaninsulin.AsshowninTable3,thehagfishanalogue(which
contains LysA9Ser and LysB9Ser substitutions, to prevent any
undesired cleavage with lysine specific protease during analogue
production) shows an affinity that was 5% of that of human
insulinsimilartotheunsubstitutedhagfishinsulin.Thereciprocal
substitutions show thatthey give the opposite effect compared to
the substitutions in human insulin. The AspA15Gln, GlyB4Gln,
AsnB13Glu, and ValB21Glu analogues show an increase in
affinity compared to that of the hagfish analogue, quite similar
to the extent of the decrease found with the reciprocal substitu-
tions. In contrast, the HisA8Thr and AspB10His analogues
exhibited a decrease in binding affinity as expected.
Dose-Response Curves for Negative Cooperativity. To
evaluate the effect of the substitutions on negative cooperativity,
we tested whether human and hagfish analogues were able to
accelerate dissociation of prebound
125I-labeled human insulin.
Both the human and hagfish analogues tested accelerated the
dissociationofprebound
125I-labeledhumaninsulinbutwereless
Table 2: Competitive Binding for the Holo Insulin Receptor with Increas-
ing Concentrations of Singly or Doubly Substituted Human Insulin
Analogues and a Fixed Concentration of
125I-Labeled Human Insulin
a
human insulin analogue Kd ( SD (nM) relative affinity
b (%)
human insulin 0.29(0.02 100
IleA10Arg 5.05( 0.84 6
LeuA13Ile 0.37(0.04 80
GlnA15Asp 0.48(0.05 63
GlnB4Gly 0.55(0.22 54
HisB10Asp 0.05(0.01 547
GluB13Asn 2.28(0.47 13
LeuB17Ile 0.44( 0.04 67
GluB21Val 1.17(0.25 25
GluB4Gly/GluB13Asn 3.71(0.66 8
aThe Kd values are averages, and the relative affinity of that of human
insulin binding to the insulin receptor [(Kd for human insulin)/(Kd for the
insulin analogue)   100%] is also shown.
bBold values show a >2-fold
change in affinity relative to that of human insulin.
Table 3: Competitive Binding for the Holo Insulin Receptor with Increas-
ing Concentrations of Singly Substituted Hagfish Insulin Analogues and a
Fixed Concentration of
125I-Labeled Human Insulin
a
hagfish insulin
analogue
Kd ( SD
(nM)
relative affinity
b
(%) for
human insulin
relative affinity
b
(%) for
hagfish insulin
human insulin 0.29 (0.02 100 2000
hagfish (KA9S, KB9S) 5.49(0.11 5 100
HisA8Thr 7.38(0.75 4 80
AspA15Gln 4.70(0.51 6 120
GlyB4Gln 2.34(0.12 13 260
AspB10His 14.46 (0.41 24 0
AspB13Glu 1.58(0.13 19 380
ValB21Glu 1.56(0.29 19 380
aTheKdvaluesareaverages(SD,andtherelativeaffinityofhumanand
hagfish (KA9S, KB9S) insulin binding to the insulin receptor [(Kd for
human insulin)/(Kd for the insulin analogue)   100%] is also shown. The
analogues have additional KA9S and KB9S substitutions to prevent
cleavage at these positions during processing.
bBold values show a more
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potent than human insulin as shown by a rightward shift in the
dose-response curves (Figures 5 and 6). All single hagfish
mutants showed no reversal of cooperativity at high concentra-
tions (Figure 6) within the range tested, as shown previously for
wild-type hagfish insulin (19), hystricomorph insulins (47), and
human insulin-like growth factor I (IGF-I) (48).
The possible reversal at high concentrations was not possible to
assess with the human substituted analogues (Figure 5) due to
insufficientmaterial,withtheexceptionofIleA10Argwhichshowed
a clear trend for a bell-shaped curve [the last point of Figure 5A is
significantly higher than the nadir of the curve (p<0.05)].
The human insulin GlnB4Gly analogue exhibited a potency
almost identical to that of accelerated dissociation of prebound
125I-labeled human insulin as human insulin, while the Glu-
B13Asn and IleA10Arg analogues exhibited the most decreased
potency compared to that of human insulin. The B4 and B13
doubly substituted analogue exhibited a higher potency than
GluB13Asn, although it had the most reduced affinity of the
human insulin analogues. In summary, the analogues ranked as
follows in terms of potency for negative cooperativity: human
insulin ≈ GlnB4Gly>GluB21Val>the double substitution (B4
and B13) > GluB13Asn > IleA10Arg. All the hagfish insulin
analogues exhibited a marked reduction in the potency of
accelerated dissociation of prebound
125I-labeled human insulin.
TheAspB10Hisanaloguehadthemostreducedpotencyofallthe
analogues, in accordance with the relative affinity described in
Table 3. Hagfish, HisA8Thr, and AspA15Glninsulin hadalmost
identical potencies, HisA8Thr having the most reduced potency.
These results correlate well with the affinities listed in Table 3,
although HisA8Thr was expected to give the second largest
reduction both in the potency of accelerated dissociation and
inthe affinity for the receptor,sincethe reciprocalsubstitution in
human insulin has been reported to increase the affinity for the
receptor3-fold.GlyB4Glnwasexpectedtohaveahigherpotency
than hagfish insulin, but it exhibited a marginally reduced
potency compared to that of hagfish. AsnB13Glu and ValB21-
Glu exhibited higher potencies than hagfish insulin, AsnB13Glu
having the highest potency of all the hagfish analogues. To sum-
marize the hagfish analogue potencies, the analogues ranked as fol-
lows: human insulin . AsnB13Glu>ValB21Glu>AspA15Gln ≈
hagfish insulin ≈ HisA8Thr>GlyB4Gln . AspB10His.
FIGURE 5: Dose-responsecurvesfornegativecooperativity(human
insulin analogues). Dissociation of prebound
125I-labeled human
insulin in the presence ofincreasingconcentrations of human insulin
(b) is illustrated in the two curves. Dissociation with increasing
concentrations of GlnB4Gly (9), IleA10Arg (þ), and the doubly
substituted analogue (1) (A) and GluB13Asn ([) and GluB21Val
(2) (B). Curves are illustrated as bound to bound at 0 M cold ligand
after dissociation for 30 min. The curves are averages of three assays
each made in duplicate. Standard deviations are shown for all the
data (smaller than symbol when not visible).
FIGURE 6: Dose-responsecurvesfornegativecooperativity(hagfish
insulin analogues). Dissociation of prebound
125I-labeled human
insulin in the presence of increasingconcentrations of human insulin
(b) is illustrated in all three curves. (A) Dissociation with increasing
concentrations of HisA8Thr (0), hagfish (KA9S, KB9S) (O), and
AspB10His(4).(B)GlyB4Gln( ),AsnB13Glu(]),andValB21Glu
(þ).(C)Hagfish(KA9S,KB9S)(O)andAspA15Gln(Θ).Curvesare
illustratedasboundtoboundat0Mcoldligandafterdissociationfor
30 min. The curves are an average of three assays each conducted in
duplicate. Standard deviations are shown for all the data (smaller
than the symbol when not visible).11290 Biochemistry, Vol. 48, No. 47, 2009 Sajid et al.
It should be mentioned that the determination of potencies in
this assay is not reliable in the case of analogues with relatively
slowkineticssincedissociationaccelerationismeasuredat30min
while it may take substantially longer for the cold analogues to
reach equilibrium during the assay; the curves in this assay move
leftward with increasing incubation times (30).
DISCUSSION
These results show that hagfish and lamprey insulins share a
set of unusual receptor binding and biological properties when
compared to most mammalian insulins. Only hystricomorph
insulins among mammalian insulins exhibit properties similar to
those of hagfish and lamprey insulins (22, 49). Insulin analogues
with single substitutions in binding site 2 also were shown to
behave ina similar way (22, 24, 50).This implies that the unusual
properties of these insulins may be explained by substitutions in
site 2, a hypothesis that has been validated in our laboratory for
the hystricomorph insulins (49) and is tested in this work for
hagfish and lamprey insulins.
Enhanced Mitogenic or Metabolic Potency Ratio of
Hagfish and Lamprey Insulins. Both hagfish and lamprey
insulins exhibit enhanced mitogenic and metabolic potency
ratios, 5.8 for lamprey and 3.8 for hagfish. This is a property
that we have seen with other insulins modified in site 2, such as
insulins mutated at A13 and B17 (22, 24).
The low biological potency of hagfish and lamprey insulin in
rat adipocytes is also in line with insulins like hystricomorph
insulins and A13 and B17 mutated insulins, where the biological
potency in lipogenesis is proportional to the association rate
rather than to the affinity. Holst et al. showed that the potency
measured after lipogenesis for 2 h correlated poorly with the
amount of analogue bound at the time where lipogenesis is
measured (“equilibrium”) but correlated strongly with the rela-
tive amounts of analogue bound within the first few minutes of
incubation (50). Thus, insulins and analogues that reach equilib-
rium quickly will appear to have a potency proportional to their
binding affinity, while those with slow kinetics like hagfish and
lamprey insulins will have potencies that appear to be propor-
tional to their association rates.
Receptor Binding and Biological Properties of Hagfish
Insulin. With regard to hagfish insulin, these results not only
confirm and extend previous findings but also reveal several
novelfeatures.AlthoughthebindingtoIM-9cellswasprolonged
to6 h and reached an apparent steadystate, the apparentaffinity
of hagfish insulin was only 4.5% at 15  C. This agrees with the
potency of 5% in competing for
125I-labeled porcine insulin
binding to IM-9 cells reported by Muggeo et al. (19)i n9 0m i n
incubations at 15  C. Muggeo et al. also found a potency of
5-10% in competing for
125I-labeled porcine insulin binding in
rat adipocytes, and Terris and Steiner (20) reported a potency of
3% in rat liver cells. These apparent affinities are consistent with
the low biological activity of hagfish insulin in stimulating
lipogenesis in rat adipocytes: 8.4% in this study, 4.6% by Emdin
et al. (51), 3.8% by Thomas et al. (16), 7% in rat fat pad by
Weitzel et al. (52) relative to that of bovine insulin, and 5-10%
for deoxyglucose transport by Muggeo et al. (19).
It isplausible that hagfish insulin’s affinity, if it was accurately
measuredattrueequilibrium,wouldbegreaterthanitsmetabolic
potency (e.g., lipogenesis in rat adipocytes). We do not believe,
however, that this implies that hagfish insulin is a partial
antagonist but rather that the potency for lipogenesis in rat
adipocytes is not determined at equilibrium but early in the
binding process, as discussed above. From a physiological view-
point, it should be noted that the hagfish lives in an environment
at ∼5  C and that the hypoglycemic response of the hagfish to
injected insulin takes 2-3d a y st od e v e l o p( 53).
In contrast, using homologous competition and Scatchard
analysis, the relative affinity of lamprey insulin for a purified
soluble human receptor ectodomain was found to be 166% on
the basis of comparison of IC50 and 203% on the basis of
comparisonofKd(seeFigure1AoftheSupportingInformation).
This high affinity for the soluble receptor confirms previous
findings of 130% based on IC50 by Conlon et al. (9) for this
insulin. The relative affinity of hagfish insulin for the purified
soluble human receptor ectodomain was determined to be 22%
of that of human insulin (see Figure 1B of the Supporting
Information). It is typical for insulin analogues with site 2 sub-
stitutions to exhibit much higher relative affinities for the soluble
ectodomain than for the cell-bound receptor, since the soluble
ectodomain exhibits primarily site 1 binding (26;J .B r a n d t ,
unpublished data).
Muggeo et al. had shown that hagfish insulin was able to
accelerate the dissociation of
125I-labeled porcine insulin with a
potencyof5% of unlabeled porcine insulin and showedthe same
maximal acceleration. A novel finding in this study is that when
125I-labeled hagfish insulin is used as the tracer, the degree of
dissociation seen in the presence of an excess of cold hagfish or
human insulin is reduced (56% of that obtainedwith
125I-labeled
human insulin), indicating a reduced negative cooperativity,
as also seen in rat adipocytes by Emdin et al. (43). The
dose-response curve for acceleration of
125I-labeled hagfish
insulin with unlabeled hagfish insulin was not bell-shaped, while
it was with human insulin, as previously reported by Muggeo
et al. (19).
The mitogenic potency of hagfish insulin in stimulating
thymidine incorporation in NIH3T3 cells overexpressing the
insulin receptor was 32% relative to that of human insulin.
Therefore,hagfishinsulinexhibitsamitogenic:metabolicpotency
ratioof3.8inourhands.Apreviousstudyreportedaratioof1.0,
but the actual data were not shown (54).
Receptor Binding and Biological Properties of Lamprey
Insulin. Both association and dissociation rates for lamprey
insulin were notably slower than that of human insulin on IM9
cells. While lamprey insulin accelerated the dissociation of
125I-
labeled human insulin, albeit with reduced potency, the data
suggest a lack of reversal with increasing concentrations of
unlabeled ligand. However, a paucity of material did not allow
use of very high concentrations of unlabeled lamprey insulin.
When
125I-labeled lamprey insulin was used as the tracer, the
degree of dissociation seen in the presence of an excess of cold
lamprey or human insulin was greatly diminished, indicating
reduced negative cooperativity. This was more pronounced with
lampreyinsulinthanwithhagfishinsulin.Therefore,theprevious
conclusion about “extraordinary conservation of ... negative
cooperativity in the most primitive vertebrate” (19), based on
the effect of unlabeled hagfish insulin on the dissociation of
125I-
labeled porcine insulin, must be tempered by the marked
attenuation of this phenomenon when these ancient insulins
are used as tracers. The affinity of lamprey insulin for the human
insulin receptor on IM9 cells was 8% of that of human insulin.
The metabolic potency of lamprey insulin in primary rat adipo-
cytes was similar to that of hagfish insulin, 9 and 8%, respec-
tively, and both insulins gave the same maximal response as
human insulin with parallel curves. The mitogenic:metabolicArticle Biochemistry, Vol. 48, No. 47, 2009 11291
potency ratio of lamprey insulin (5.8) was greater than that seen
with hagfish insulin (3.8).
Structure-Activity Relationships of Hagfish and Lam-
prey Insulins. The structural reasons for the aberrant binding
and biological behavior of hagfish insulin have so far eluded
explanation. Hagfish insulin has 33 amino acids in common with
human insulin (Table 1 of the Supporting Information) and a
very similar three-dimensional structure (55). Its ability to
dimerize is conserved, but it does not form hexamers because
of the HisB10 to Asp substitution (55). The “classical binding
surface” isconserved(Table 1), and two substitutions arepresent
that confer an increased affinity when introduced into human
insulin. The first one is the ThrA8 to His mutation, a mutation
that markedly increases the affinity of human insulin to 327% in
HepG2cells(31)and300%inIM-9lymphocytes(47,56).Turkey
and chicken insulins also have His at A8 and display increased
affinity (57). The biological activity of HisA8 human insulin is
accordingly increased (58). The second favorable substitution is
the HisB10 to Asp substitution, which enhances 3-5-fold the
affinity and activity of human insulin (31, 46). Thus, hagfish
insulin would in fact be predicted to have a substantially
higher affinity than human insulin if only the classical binding
surface was involved. It is clear, therefore, that there must be
other contacts between insulin and the receptor outside the
classical binding surface, which when substituted in hagfish
insulin explain the loss of affinity, a conclusion also reached by
Baker et al. (14).
Recent investigations of a number of insulin analogues mu-
tatedatvariouspositionsbysite-directedmutagenesishaveledus
to conclude that there is indeed a second binding surface on the
insulin molecule that coincides with insulin’s hexamerization
surface (15, 22, 26). It comprises in human insulin residues
SerA12, LeuA13, GluA17, HisB10, GluB13, and LeuB17
(Table 1). The central helix of the B chain is at the confluence
of both surfaces and is clearly a central motif in binding to the
insulin receptor (59, 60).
By excluding substitutions also found in other high-affinity
insulins and given the similarity in binding properties between
human analogues mutated in site 2 and those of hagfish insulin,
we decided to focus on hagfish residues substituted in site 2,
namely, LeuA13Ile, HisB10Asp, GluB13Asn, and LeuB17Ile,
and to test the effect of reciprocal substitutions at these residues
in hagfish and human insulins. We also tested the effect of
substitution of HisA8 to Thr in site 1 in hagfish insulin.
Wealso explored afewresidues outsidethe sofar known site1
and site 2.
Wethoughtthat the substitution ofGlnB4 withGlyinhagfish
insulin and Thr in lamprey insulin could also possibly contribute
to thealtered binding since B4 isconservedin allmammalsbut is
altered in other low-affinity insulins (Arg in guinea pig, Lys in
chinchilla, and Glu in amphioxus).
Baker et al. (14) suggested that the GluB21 to Val substitution
may be relevant for the low activity of hagfish insulin. However,
mutation of B21 to Ala in human insulin increases the affinity to
230%forthelow-affinitysolublereceptor(61)and226%inIM-9
cells(26).Incontrast,inarecentstudy,an∼2-folddecreaseinthe
level of binding to receptors on the human placental membrane
was seen, when GluB21 was substituted with Ala (62). Studies
conducted in our laboratory also indicate that this position
is important for receptor binding, since substitutions to
Arg, Gly, Pro, Ser, and Thr all show a decrease in affinity of
>2-fold (63).
Near the completion of this project, we became aware that the
IleA10 to Arg substitution in hagfish insulin and IleA10 to Lys
substitution in lamprey insulin may also have a deleterious effect
on binding. We initially ignored this position because it is not
conservedinevolutionandischangedtoeitherThr,Val,orProin
other insulins (14). For unknown reasons, it was also ignored in
the previous alanine scanning of insulin (26, 61). However,
Gauguin et al. (64) recently showed that substitution of IleA10
with Ser as in IGF-I and IGF-II results in a 5-fold loss of affinity
and contributes significantly to the low affinity of the IGFs for
the insulin receptor. Like A8, A10 lies on the periphery of site 1.
Hagfish and lamprey insulins are the only forms in which a
charged substitution at A10 is present. It was not possible to test
the human insulin with a Lys substitution at A10 like in lamprey
insulin since the analogue would be proteolyzed at this position
during processing, but the Arg substitutions at this position in
human insulin were tested.
Receptor Binding of Human and Hagfish Analogues. On
the basis of the structure-activity relationship of hagfish insulin
discussedabove,ninehumaninsulinandsevenhagfishanalogues
in which residues at different positions were substituted recipro-
cally were produced (Figure 7A,B), and their binding affinities
for the holoreceptor on IM9 cells were determined (Tables 2 and
3).Furthermore,therelativepotenciesofaccelerateddissociation
of prebound
125I-labeled human insulin (testing for negative
cooperativity) were analyzed for selected analogues (Figures 5
and 6).
Thehumaninsulinanalogueswithhagfish-likesubstitutionsat
positionsA10,B13,andB21exhibiteddecreasesinaffinityof16-,
8-, and 4-fold, respectively. While the B4 substitution decreased
the affinity to 53% which is borderline, the double mutant
GlnB4Gly/GluB13Gly showed a 12.5-fold decreased affinity,
greater than that of each single mutation, suggesting that B4
indeed contributes to binding affinity. In contrast, substitution
of HisB10 with Asp increased the affinity as previously shown
(31, 46). The combined effect of all the substitutions mentioned
above would be expected to yield an affinity much lower than
that observed for hagfish insulin, suggesting that they are not
strictly additive.
Reciprocally, human-like mutations GlyB4Gln, AsnB13Glu,
andValB21Gluinhagfishinsulinincreasedtheaffinityofhagfish
insulin for the human insulin receptor 2.6-, 3.8-, and 3.8-fold,
respectively, while HisA8Thr and AspB10His decreased it to
80 and 40%, respectively. This also supported a minor role of B4
in receptor binding.
When these analogues were examined for their ability to
induce negative cooperativity via dose-response curves for
accelerated dissociation (Figures 5 and 6), the most striking
feature was that every single substitution in hagfish insulin
produced analogues that induced a sigmoid rather than bell-
shaped dose-response curve. This has been observed previously
for hagfish insulin (and in this work for lamprey insulin), as well
as for insulin analogues mutated at positions A13 and B17 in site
2( 22), hystricomorph insulins (22, 49), and IGF-I binding to the
IGF-I receptor (22, 30, 47). The effect of site 2 mutations on the
bell-shaped curve has been fully identified in mathematical
modeling of the insulin and IGF-I receptors as harmonic
oscillators,basedonDeMeyts’bivalentcross-linkingmodel(30).
Our initial interpretation for the lack of reversal of negative
cooperativity at the IGF-I receptor at high concentrations of
IGF-I was that there may not be sufficient space for two IGF-I
molecules (due to the presence of the C-peptide) to fit into the11292 Biochemistry, Vol. 48, No. 47, 2009 Sajid et al.
second pair of receptor sites 10 and 2 for cross-linking (30).
Obviously, this argument cannot hold for the substituted human
analogues studied here. A more plausible argument is that to
prevent rebinding of the first cross-link, the rate of formation of
the second cross-link must be faster than the rate of reclosing of
the first. A slow association rate constant for receptor site 2 may
explain the lack of reversal as demonstrated by mathematical
simulation in Figure 8. The possibility that a reversal would be
observedatmuchhigherconcentrationscannotbeexcluded.This
concept probably also applies to the IGF-I receptor since
Lawrence et al. have recently shown by small-angle X-ray
scattering that the soluble IGF-I receptor ectodomain binds up
to three IGF-I molecules (65).
The observed potencies for the accelerated dissociation were
generally in line with the observed changes in affinity, with the
exception of those of GlnB4Gly human insulin which was not
different from human insulin and GlyB4Gln hagfish insulin
which was slightly lesspotentthanhagfishinsulin, showing again
a marginal effect of this substitution. It should be stressed,
however, that the dose-response curve was done after dissocia-
tion for 30 min, and it is known that site 2 mutations can
markedlydecreasetheassociationrateoftheanalogue(22,24).It
means that a longer time period may have been needed to
determine the exact potency of the analogues in this assay, and
tocorrelatethemwiththerelativeaffinityobservedincompetiton
assays.
StructuralBasisoftheLowAffinityandBindingProper-
ties of Lamprey Insulin. On the basis of the findings described
above, it is possible to generate a reasonable hypothesis for why
lamprey insulin has properties similar to those of hagfish insulin,
although they are less pronounced (somewhat higher association
rate, higher affinity, and more acceleration of dissociation by
unlabeled ligand).
Lamprey insulin shares with hagfish insulin a positively
charged substitution at A10 (Lys vs Arg), which is deleterious
in hagfish insulin. It is interesting that like hagfish and lamprey
insulins, human IleA10Arg was found to have a much higher
affinity for a soluble receptor preparation [60% vs 6% as
observed in our system (data not shown)]. Such discrepancies
have been observedwithsite2insulinsubstitutions.Itisnotclear
if A10 belongs to site 1 or 2 (it is located between A8 which we
have assigned to site 1 and A12 which we have assigned to site 2,
on the basis of their respective involvement in dimerization vs
hexamerization). The separation between sites 1 and 2 is
obviously somewhat speculative in the absence of a structure of
the insulin receptor complex, and the two surfaces may in fact be
more of a continuum.
Residues A17 and B13 in the hexamer-forming surface are
intact, and B21 is conservatively changed from Glu to Asp, in
contrast with hagfish insulin. However, lamprey insulin lacks the
positive effect of the HisB10 to Asp substitution.
FIGURE 7: Summaryofthecontributionofeachaminoacid.PanelA
illustrates the effect of each hagfish insulin substitution in human
insulin,andpanelBillustrateshumaninsulinsubstitutionsinhagfish
insulin. The substitutions marked in red led to a significant decrease
in affinity, while the substitutions that led to a significant increase in
affinityaremarkedingreen.Thebluesubstitutionshadnosignificant
change in affinity. The atomic coordinates [(A) human insulin
(Protein DataBank entry 1G7A) and (B) hagfish insulin (a gift from
G. G. Dodson)] were used to construct the diagrams. Molecular
graphic images were produced using PyMol from DeLano Scientific
LLC.
FIGURE 8: Simulated dose-responsecurvesfor negative cooperativ-
ity. The curves were generated using a harmonic oscillator model as
previouslydescribed(seeref30foradetailedexplanation).Themodel
contains five binding parameters: a1, rate constant for association
with site 1; a2, rate constant for association with site 2; d1,r a t e
constantfordissociationfromsite1;d2,rateconstantfordissociation
from site 2; and kcr, cross-linking constant. For the values of the
constants,seeref30.Thesimulationshowsthatfordecreasingvalues
of a2, the dose-response curve goes from bell-shaped to sigmoid
within the range of ligand concentrations used in the experiments.Article Biochemistry, Vol. 48, No. 47, 2009 11293
Likehagfishinsulin,italsoharborsapotentiallydeleteriousB4
mutation, in this case Gln to Thr. However, most interestingly,
LeuB17 in the hexamer-forming surface is mutated to Val. In
human insulin, as mentioned earlier, single mutations at this
position to Ala or Ser are sufficient toreduce the affinity ∼3-fold
and to induce the peculiar binding behavior seen in hagfish,
lamprey, and hystricomorph insulins. Thus, this position is
clearly sensitive to the nature of the particular amino acid. It
may seem that a Leu to Val substitution is a relatively con-
servative substitution; however, Leu and Val are not always
equivalent, and such substitutions have been found in key
proteins in clinical syndromes: first, in insulin itself, where a
ValA3 to Leu mutation was found in a diabetic patient (insulin
Wakayama ofweakpotency, 0.2%) (66) andseconda ValA30 to
Leu mutation in transthyretin that results in familial amyloid
polyneuropathy (67). Systematic mutagenesis at B17 using a
solubilized receptor showed that while substitutions at B17 with
Met, Phe, and Trp were well tolerated, other substitutions
reducedaffinity2-6-fold;substitutiontoValreducedtheaffinity
2.5-fold (59). It should be noted that using affinity alone to judge
theimpactofmutationsinsite2mayunderestimatetheimpactof
substitutions since reciprocal changes in association and disso-
ciation rates are observed (slow on rate, slow off rate).
In summary, this work confirms and extends previous ob-
servations on the receptor binding and biological properties of
hagfish insulin and describes very similar properties for lamprey
insulin. It provides, at last, a rational explanation for these
properties in light of a proposed bivalent receptor binding model
and, via comparison of the data obtained with those known for
other mutated analogues, reduced the number of candidate
substitutions to a small number that was tested by reciprocal
site-directed mutagenesis.
Our data also add credibility to our proposal that the set of
unusual properties described here may represent the binding
mode of the ancestral insulin, which may have been more of a
mitogen than a metabolic regulator (22) as also proposed by
Chan and Steiner (68).
It will be of great interest to investigate in detail the properties
of the more ancient insulin-like molecules such as those from
amphioxus and invertebrates.
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